Skip to main content
Clinical Trials/DRKS00033377
DRKS00033377
Not yet recruiting
Not Applicable

Quality assurance initiative for systemic treatment in metastatic colorectal cancer - QA-mCRC

Charite Berlin - Medizinischen Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CCM)0 sites2,100 target enrollmentApril 9, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C18
Sponsor
Charite Berlin - Medizinischen Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CCM)
Enrollment
2100
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 9, 2024
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Charite Berlin - Medizinischen Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CCM)

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of mCRC with primarily non\-resectable metastases in QIII/23 and QIV/23 and 1st line systemic treatment or 2nd line systemic treatment therapy in the metastatic setting

Exclusion Criteria

  • Patients with non\-metastatic disease
  • Patients with only primarily resectable metastases
  • Patients are not suitable for systemic therapy due to reduced general condition or concomitant diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials